Matinas BioPharma announces planned CFO departure with no disagreement

Rhea-AI Filing Summary

Matinas BioPharma Holdings, Inc. reported a planned leadership change. On November 18, 2025, Chief Financial Officer Keith Kucinski informed the company that he intends to resign from his role, effective January 17, 2026, to pursue other opportunities. The company stated that his decision is not due to any disagreement regarding its operations, policies, or practices, indicating an orderly transition rather than a dispute-driven departure.

false 0001582554 0001582554 2025-11-18 2025-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2025

MATINAS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38022		46-3011414
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer ID Number)

1545 Route 206 South, Suite 302 Bedminster, New Jersey		07921
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (908) 484-8805

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock		MTNB		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 18, 2025, Keith Kucinski, Chief Financial Officer of Matinas BioPharma Holdings, Inc. (the “Company”), notified the Company of his intention to resign from his position as Chief Financial Officer, effective January 17, 2026, to pursue other opportunities. Mr. Kucinski’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MATINAS BIOPHARMA HOLDINGS, INC.
Dated: November 21, 2025	By:	/s/ Jerome D. Jabbour
	Name:	Jerome D. Jabbour
	Title:	Chief Executive Officer

FAQ

What leadership change did Matinas BioPharma (MTNB) announce?

Matinas BioPharma announced that its Chief Financial Officer, Keith Kucinski, has notified the company of his intention to resign from his position as CFO, effective January 17, 2026.

Why is the Matinas BioPharma (MTNB) CFO resigning?

The CFO, Keith Kucinski, informed Matinas BioPharma that he is resigning to pursue other opportunities. No additional reasons were provided in the disclosure.

Did the Matinas BioPharma (MTNB) CFO resign due to a disagreement with the company?

The company stated that Mr. Kucinski’s resignation was not the result of any disagreement with Matinas BioPharma on matters related to its operations, policies, or practices.

When will the Matinas BioPharma (MTNB) CFO resignation become effective?

The resignation of Chief Financial Officer Keith Kucinski will become effective on January 17, 2026.

Who signed the Matinas BioPharma (MTNB) report about the CFO resignation?

The report was signed on behalf of Matinas BioPharma by Jerome D. Jabbour, who is the company’s Chief Executive Officer.

What stock exchange is Matinas BioPharma (MTNB) listed on?

Matinas BioPharma’s common stock, trading under the symbol MTNB, is listed on the NYSE American exchange.